Expression of P53,mrp and C-Erbb2 in Non-Small Cell Lung Cancer and Its Clinicopathological Significance
徐裕金,王连聪,郑晓,刘冠,王跃珍,赖宵晶,李健强
2009-01-01
Abstract:Objective To investigate the expression of p53,c-erbB2 and MRP and its clinicopathological significance in non-small-cell lung cancer (NSCLC). Methods The expressions of p53,c-erbB2 and MRP protein were detected in 152 tumor samples of primary NSCLC by immunohistochemical staining using a polyclonal antibody. The correlation of protein expression with clinicopathologic parameters was analyzed. Results The positive rates of p53,c-erbB2 and MRP expression were 53.9% (82/152), 44.1% (67/152) and 43.4% (66/152), respectively. There was significantly correlation of p53 expression with gender,tumor differentiation,TNM stage and lymph metastasis (P<0.05),but there was no correlation of c-erbB2 expression with clinicopathologic parameters in NSCLCs. MRP positive rate in adenocarcinoma was significantly higher than that in squamous-cell carcinomas (67.6% vs 33.0%,P<0.05). Overall survival was significantly correlated with the co-overexpression of p53,c-erbB2 and MRP proteins. The 1-,2-,3-year survival rates in patients with co-positive p53,c-erbB2 and MRP were 72.6%,54.8% and 32.2%,respectively,which were lower than those in patients with co-negative expression (92.1%,78.5% and 63.4%; P=0.02,0.01 and 0.00).The survival rate in patients who received surgery alone with co-positive expression was lower than that in patients with co-negative expression (P<0.05); and the survival rate of patients who had surgery plus chemotherapy with co-positive c-erbB2 and MRP was lower than that with co-negative (P=0.01). Cox′s model analysis showed that c-erbB2 expression and cell differentiation were independent prognostic factors in patients with completely resected NSCLC. Conclusion p53,c-erbB2 and MRP may be useful indicators in prognosis of NSCLC.